|
🐜
|
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
31 auth.
J. Hugosson,
M. Roobol,
M. Månsson,
T. Tammela,
M. Zappa,
V. Nelen,
M. Kwiatkowski,
M. Luján,
S. Carlsson,
K. Talala,
H. Lilja,
L. Denis,
F. Recker,
Á. Páez,
D. Puliti,
...
A. Villers,
X. Rébillard,
T. Kilpeläinen,
U. Stenman,
R. Godtman,
K. Stinesen Kollberg,
S. Moss,
P. Kujala,
K. Taari,
A. Huber,
T. H. van der Kwast,
E. Heijnsdijk,
C. Bangma,
H. D. de Koning,
F. Schröder,
A. Auvinen
|
8 |
2019 |
8
🐜
|
|
🦁
|
Quality-of-life effects of prostate-specific antigen screening.
22 auth.
E. Heijnsdijk,
E. Wever,
A. Auvinen,
J. Hugosson,
S. Ciatto,
V. Nelen,
M. Kwiatkowski,
A. Villers,
Á. Páez,
S. Moss,
...
M. Zappa,
T. Tammela,
T. Mäkinen,
S. Carlsson,
I. Korfage,
M. Essink‐bot,
S. Otto,
G. Draisma,
C. Bangma,
M. Roobol,
F. Schröder,
H. D. de Koning
|
8 |
2012 |
8
🦁
|
|
🐜
|
Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies
28 auth.
J. Mandelblatt,
N. Stout,
C. Schechter,
Jeroen J. van den Broek,
D. Miglioretti,
Martin Krapcho,
A. Trentham-Dietz,
Diego F. Munoz,
Sandra J. Lee,
D. Berry,
N. V. van Ravesteyn,
O. Alagoz,
K. Kerlikowske,
A. Tosteson,
A. Near,
...
A. Hoeffken,
Yaojen Chang,
E. Heijnsdijk,
G. Chisholm,
Xuelin Huang,
Hui Huang,
M. Ergun,
R. Gangnon,
B. Sprague,
S. Plevritis,
E. Feuer,
H. D. de Koning,
K. Cronin
|
7 |
2016 |
7
🐜
|
|
🐬
|
Interpreting Overdiagnosis Estimates in Population-based Mammography Screening
R. de Gelder,
E. Heijnsdijk,
N. V. van Ravesteyn,
J. Fracheboud,
G. Draisma,
H. D. de Koning
|
7 |
2011 |
7
🐬
|
|
🐜
|
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
22 auth.
A. Tsodikov,
R. Gulati,
E. Heijnsdijk,
P. Pinsky,
S. Moss,
S. Qiu,
T. D. de Carvalho,
J. Hugosson,
C. Berg,
A. Auvinen,
...
G. Andriole,
M. Roobol,
E. Crawford,
V. Nelen,
M. Kwiatkowski,
M. Zappa,
Marcos Lujn,
A. Villers,
E. Feuer,
H. D. de Koning,
A. Mariotto,
Ruth Etzioni
|
7 |
2017 |
7
🐜
|
|
🦁
|
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
E. Heijnsdijk,
A. D. Kinderen,
E. Wever,
G. Draisma,
M. Roobol,
H. J. Koning
|
7 |
2009 |
7
🦁
|
|
🐜
|
Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.
19 auth.
Diego F. Munoz,
A. Near,
N. V. van Ravesteyn,
Sandra J. Lee,
C. Schechter,
O. Alagoz,
D. Berry,
E. Burnside,
Yaojen Chang,
G. Chisholm,
...
H. D. de Koning,
Mehmet Ali Ergun,
E. Heijnsdijk,
Hui Huang,
N. Stout,
B. Sprague,
A. Trentham-Dietz,
J. Mandelblatt,
S. Plevritis
|
7 |
2014 |
7
🐜
|
|
🦁
|
Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
19 auth.
E. Heijnsdijk,
T. M. de Carvalho,
Anssi Auvinen,
M. Zappa,
V. Nelen,
M. Kwiatkowski,
A. Villers,
A. Páez,
S. Moss,
T. Tammela,
...
F. Recker,
L. Denis,
S. V. Carlsson,
E. Wever,
C. Bangma,
F. H. Schröder,
M. Roobol,
J. Hugosson,
H. de Koning
|
7 |
2015 |
7
🦁
|
|
🐜
|
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.
17 auth.
I. Lansdorp-Vogelaar,
R. Gulati,
A. Mariotto,
C. Schechter,
T. D. de Carvalho,
Amy B. Knudsen,
N. V. van Ravesteyn,
E. Heijnsdijk,
C. Pabiniak,
M. van Ballegooijen,
...
C. Rutter,
K. Kuntz,
E. Feuer,
Ruth Etzioni,
H. D. de Koning,
A. Zauber,
J. Mandelblatt
|
7 |
2014 |
7
🐜
|
|
🐜
|
Is prostate cancer different in black men? Answers from 3 natural history models
8 auth.
A. Tsodikov,
R. Gulati,
T. D. de Carvalho,
E. Heijnsdijk,
Rachel Hunter-Merrill,
A. Mariotto,
...
H. D. de Koning,
Ruth Etzioni
|
6 |
2017 |
6
🐜
|
|
🐜
|
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
11 auth.
A. Vickers,
D. Sjoberg,
D. Ulmert,
E. Vertosick,
M. Roobol,
I. Thompson,
...
E. Heijnsdijk,
H. D. de Koning,
Coral Atoria-Swartz,
P. Scardino,
H. Lilja
|
6 |
2014 |
6
🐜
|
